Physician profile
Blake Doerr
NPI 1588345110
$4,248.99
in general payments reported to CMS, 2019-2025
24 companies · $972 in 2025
The $972 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $790 · 2024: $2,487 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,069 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,068.87 |
| Education | $180.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $857.40 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $644.45 | 2023-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $467.08 | 2023-2025 | |
| Glaxosmithkline, LLC. | $412.31 | 2023-2025 | Trelegy Ellipta, Nucala |
| Amgen INC. | $283.67 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $213.96 | 2023-2025 | Cuvitru, Takhzyro |
| Biocryst US Sales Co., LLC | $211.55 | 2023-2025 | Orladeyo |
| Csl Behring | $189.88 | 2024 | Haegarda |
| Genentech USA, INC. | $162.12 | 2023-2025 | Xolair |
| Octapharma USA, INC. | $133.09 | 2023-2025 | Cutaquig |
| Blueprint Medicines Corporation | $111.55 | 2023-2025 | Ayvakit |
| Sumitomo Pharma America, INC. | $74.11 | 2025 | Gemtesa |
| Incyte Corporation | $62.88 | 2024-2025 | Opzelura |
| Janssen Biotech, INC. | $60.12 | 2025 | Erleada |
| Lilly USA, LLC | $58.04 | 2025 | Ebglyss |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $53.59 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $51.19 | 2025 | Adstiladrin |
| Grifols USA, LLC | $46.97 | 2023 | Xembify |
| Immunitybio, INC. | $44.49 | 2025 | |
| Progenics Pharmaceuticals, INC. | $34.34 | 2025 | |
| Novartis Pharmaceuticals Corporation | $33.10 | 2025 | |
| Merck Sharp & Dohme LLC | $19.35 | 2023 | |
| Hikma Pharmaceuticals USA | $14.79 | 2024 | Ryaltris |
| Organon LLC | $8.96 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Doerr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.